- Previous Close
2.8000 - Open
2.6600 - Bid 2.6600 x --
- Ask 2.7400 x --
- Day's Range
2.6600 - 2.6600 - 52 Week Range
2.6600 - 24.2000 - Volume
740 - Avg. Volume
25 - Market Cap (intraday)
92.843M - Beta (5Y Monthly) 0.40
- PE Ratio (TTM)
-- - EPS (TTM)
-2.8800 - Earnings Date Aug 9, 2024 - Aug 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
62.14
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company
www.rapt.comRecent News: 0RA.F
View MorePerformance Overview: 0RA.F
Trailing total returns as of 6/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0RA.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0RA.F
View MoreValuation Measures
Market Cap
94.45M
Enterprise Value
-32.20M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.80
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-39.60%
Return on Equity (ttm)
-67.20%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-118.05M
Diluted EPS (ttm)
-2.8800
Balance Sheet and Cash Flow
Total Cash (mrq)
141.58M
Total Debt/Equity (mrq)
4.83%
Levered Free Cash Flow (ttm)
-65.35M